Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||MEDI1873||Phase I||Actionable||In a Phase I trial, patients with either non-small cell lung carcinoma, head and neck squamous cell carcinoma, or colorectal cancer demonstrated a best overall response of stable disease in 42.5% (17/40) and stable disease for 24 weeks or more in 17.5% (7/40) and 52.5 weeks or more in 7.5% (3/40) when treated with MEDI1873 (Annals of Oncology (2018) 29 (suppl_8); NCT02583165).||detail...|
|PubMed Id||Reference Title||Details|
|A Phase 1 study of MEDI1873, a novel GITR agonist, in advanced solid tumors||Full reference...|